Psoriasis
Conditions
Brief summary
Main research purpose 1. Quantitative analysis of the total amount of radioactivity in excreta (urine and feces) of male healthy subjects after oral administration of \[14C\]HPP737, to obtain the cumulative excretion rate and main excretion routes of human radioactivity; 2. To identify the main metabolites in the offspring of \[14C\]HPP737 in healthy male subjects, and to determine the main biotransformation pathway and main metabolite structure; 3. To investigate the distribution of total radioactivity in whole blood and plasma and the pharmacokinetics of total plasma radioactivity in healthy male subjects after a single oral administration of \[14C\]HPP737. Participants will: 1. Take Investigational product once 2. Stay in the clinic about 7 days for checkups and tests 3. Report their symptoms
Interventions
DRUGHPP737
\[14C\]HPP737 oral preparation, 20mg（150μCi）, once
Sponsors
Newsoara Biopharma Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
1. Chinese healthy adult males, aged 18-45 years (including boundary values); 2. The body weight of the subject is not less than 50kg, and the body mass index (BMI) is between 19.0 and 26.0kg/m2 (including the boundary value); 3. The subject has no sperm donation plan during the trial period and within six months after the completion of the trial, and the subject and his or her partner have no birth plan during the trial period and within six months after the completion of the trial and voluntarily take strict contraceptive measures (see Appendix 4 for details); 4. Fully understand the purpose and requirements of the trial, voluntarily participate in the clinical trial and sign the written informed consent, and be able to complete the whole process of the trial according to the requirements of the trial.
Exclusion criteria
1. Those who have undergone comprehensive physical examination, vital signs, laboratory examination (blood routine, blood biochemistry, coagulation test, urine routine, infectious disease screening, thyroid function, stool routine + occult blood), chest X-ray (positive position), anal digital examination, abdominal B-ultrasound (liver, bile, pancreas, spleen and kidney), urinary system B-ultrasound, and heart color ultrasound with clinical significance; 2. During the screening period, any ECG abnormalities determined by the investigators to be clinically significant, including but not limited to electrocardiograms with machine reading abnormalities: Fridericia's formula (QTcF=QT/ (RR\^0.33)) corrected QT interval (QTcF) \>450 msec, QRS\>110 msec, frequent atrial or ventricular premature beats; 3. Patients with abnormal color vision, retinitis pigmentosa, macular degeneration, nonarteriotic anterior ischemic optic neuropathy (NAION), or other fundus history deemed unsuitable by the investigators; 4. Allergic constitution, such as people who are known to be allergic to two or more substances, or have allergic diseases, or have a history of allergy to PDE4 inhibitors or similar drugs or their excipients; 5. Habitual constipation or diarrhea, a history of malabsorption syndrome, or a history of severe nausea, vomiting, diarrhea, and constipation within one week before the screening period; 6. have difficulty swallowing or any condition that may affect drug absorption (e.g., gastrectomy, cholecystectomy, gastric bypass, duodenotomy, colectomy); 7. Have a history of clinically serious disease or any disease or condition that the investigator believes may affect the test results, including but not limited to a history of digestive, circulatory, respiratory, endocrine, nervous, urinary, or blood, immune, psychiatric, or metabolic diseases; 8. Previous history of organic heart disease, heart failure, myocardial infarction, angina pectoris, torsional ventricular tachycardia, ventricular tachycardia, QT prolongation syndrome or family history (genetic proof or close relatives at a young age due to sudden cardiac death); 9. Major surgery or surgical incision not fully healed within 6 months prior to screening; Major surgery includes, but is not limited to, any surgery where there is a significant risk of bleeding, extended period of general anesthesia, or open biopsy or significant traumatic injury; 10. Previous active bleeding (such as peptic ulcer, intracranial hemorrhage, skin ecchymosis, gingival bleeding); History of any medical condition that may increase the risk of bleeding (e.g. tumor bleeding, spontaneous hematoma, eye bleeding, hemoptysis, gastrointestinal bleeding or ulcers, hematuria, reproductive system bleeding, traumatic hematoma/bleeding and recurrent epistaxis/gingival bleeding/subcutaneous or skin bleeding, etc.) within 6 months prior to screening; 11. Hemorrhoids or perianal disease accompanied by regular/blood in the stool, or positive stool occult blood test during the screening period; 12. Use of any drug that affects drug metabolism enzymes or transporters (P-gp and BCRP) in the 30 days prior to screening, as detailed in Appendix 5; 13. Have taken any prescription drugs, over-the-counter drugs, Chinese herbs or food supplements (vitamins, calcium supplements) in the 14 days prior to screening and before dosing; 14. Those who have taken any clinical trial drug or participated in any other clinical trial (including drug and device clinical trials) within 3 months prior to the screening period; 15. Those who have lost blood or donated blood (≥400mL) within 3 months before screening, or received blood transfusion or blood components within 1 month, or plan to donate blood within 3 months after the end of this trial; 16. Smokers who smoked more than 5 cigarettes per day or habitually used nicotine-containing products in the 3 months prior to the screening period, or were unable to stop using any tobacco products during the trial period; 17. Regular alcohol consumption in the six months prior to screening, i.e. drinking more than 14 units of alcohol per week (1 unit =285mL of beer or 25mL of 40% alcohol spirits or 100mL of wine), or a positive alcohol breath test, or unable to abstain during the test period; 18. Drug abuse or drug use history, or drug abuse screening positive; 19. Habitual or excessive (more than 8 cups a day, 1 cup =250mL) consumption of grapefruit juice, tea, coffee and/or caffeinated beverages, and unable to abstain during the trial period; 20. Those who have special requirements for diet and cannot comply with a unified diet; 21. Workers who require long-term exposure to radiation, or who have had significant radiation exposure (≥2 chest/abdominal CT, or ≥3 other types of X-rays) in the year prior to administration, or who have participated in radiopharma labeling tests; 22. Patients with a history of needle fainting and blood fainting, difficulty in blood collection or inability to tolerate venous puncture blood collection; 23. Those who had been vaccinated within 1 month prior to screening or planned to be vaccinated during the trial period; 24. Subjects whose compliance is considered poor by the investigator, or who have other factors unsuitable for participation in this trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cmax (peak concentration) | Up to 12 months | radiation pharmacokinetic parameter |
| Tmax (peak time) | Up to 12 months | radiation pharmacokinetic parameter |
| AUC0-T (area under drug time curve) | Up to 12 months | radiation pharmacokinetic parameter |
| AUC0-∞ (area under drug time curve) | Up to 12 months | radiation pharmacokinetic parameter |
| t1/2 (elimination half-life) | Up to 12 months | radiation pharmacokinetic parameter |
| CL/F (apparent clearance) | Up to 12 months | radiation pharmacokinetic parameter |
| Vd/F (apparent volume of distribution) | Up to 12 months | radiation pharmacokinetic parameter |
| MRT (mean residence time) | Up to 12 months | radiation pharmacokinetic parameter |
| Cumulative drug excretion(Urine) | Up to 12 months | Radioactive excretion corresponding to urine samples |
| Cumulative drug excretion(stool) | Up to 12 months | Radioactive excretion corresponding to stool samples |
| Major metabolite | Up to 12 months | The main metabolites in plasma, urine and fecal samples were identified by liquid chromatography-mass spectrometry (LC-MS), and radioisotope metabolites were analyzed to provide the main biotransformation pathway of HPP737 in human body. |
Countries
China
Contacts
Primary ContactJason Chen
Outcome results
None listed